Heather Thompson, Senior Editor As is the case with many medical device industry suppliers, Trelleborg has engaged in a spate of acquisitions to better serve the growing needs of its OEM customers for drug-device combo products and more. Last year, Trelleborg, Sweden–based Trelleborg announced the acquisition of Tustin, California–based Specialty Silicone Fabricators. They’ve made three […]
Business/Financial News
Teva Pharma CEO Vigodman steps down | Personnel Moves, February 7, 2017
Teva Pharmaceuticals (NYSE:TEVA) said this week that CEO Erez Vigodman has stepped down from their position at the head of the world’s biggest generic drugmaker. Vigodman’s exit from the company will take effect immediately, with board chair Yitzhak Peterburg taking on the interim role of chief exec. Israel-based Teva has seen shares plummet after a series of […]
Pulmatrix updates on $3m offering
Pulmatrix (NSDQ:PULM) today updated pricing on an upcoming $3.3 million offering, looking to float 950,000 shares at $3.50 per share. The company said it expects to collect $3.1 million after paying for placement agent fees, which it calculated at $216,125. H.C. Wainwright & Co are acting as exclusive placement agents for the offering, according to an […]
Medtech stories we missed: Feb. 3, 2017
From disappointing Getinge earnings to a $2.25 billion U.S. Defense Department contract for Cardinal Health to a host of 510(k) clearances, here are seven recent medtech stories that are still worth a mention. 1. Getinge disappoints on earnings—again Getinge stock took a nearly 10% tumble last week after releasing earnings that Reuters says lagged analyst […]
5 key takeaways from Emergo’s medical device industry outlook
By Stewart Eisenhart, Emergo Group Emergo’s latest survey of more than 3,000 medical device industry participants finds renewed focus among companies on US and European markets, as well as more bearish expectations for BRIC markets and greater challenges addressing regulatory compliance. Get the full story here at the Emergo Group’s blog. The opinions expressed in […]
Orchard Therapeutics, UCLA land $20m for stem cell clinical trial
Orchard Therapeutics and researchers from the University of California Los Angeles Broad Stem Cell Research have been awarded $20 million from the California Institute for Regenerative Medicine’s governing to fund a clinical trial for adenosine deaminase deficiency. The rare, inherited disorder is caused by mutations in a gene that encodes for adenosine deaminase. This results […]
Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy
Allergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio. Washington, D.C.-based Chase is developing a combination therapy of an acetylcholinesterase inhibitor and a cholinergic blocker in the hopes of improving cognition in patients with Alzheimer’s disease. The acetylcholinesterase inhibitors available on the […]
Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU
Immunovaccine Inc. said today that the European Medicines Agency granted orphan drug designation for its immunotherapy candidate for ovarian cancer in the EU. Orphan drug designation is granted to medicines intended for disease with a prevalence no greater than 5 in 10,000 people. According to the Nova Scotia-based company, ovarian cancer affects 3 per 10,000 […]
Athenex, Lilly ink clinical collaboration for 1st oral formulation of paclitaxel
Athenex said today that it inked a clinical collaboration deal to conduct a phase Ib study for its oral form of paclitaxel, Oraxol, with Eli Lilly‘s (NYSE:LLY) vascular endothelial growth factor (VEGF) receptor 2 antagonist, Cyramza. Patients with advanced gastric and esophageal cancer will be enrolled in 2017 at sites in the U.S. and Asia, where […]
PixarBio raises $7m for non-addictive morphine alternative
PixarBio (OTC:PXRB) raised $7 million for its biomaterial-based opioid alternative for post-operative acute and chronic pain relief, about 18% of its $40 million equity financing according to a regulatory filing that the Medford, Mass.-based company filed yesterday. The company’s drug delivery product, NeuroRelease, is an injectable morphine replacement therapy for use in the surgical/hospital setting, the […]
